Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 20.42% is 104% above its 5-year average of -489.66%, near the high end of its 5-year range (-3273.09%–243.59%).
4.41% above its 12-month average of 19.56%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 243.59%.
OPERATING MARGIN
20.42%
OPERATING MARGIN AVG TTM
19.56%
OPERATING MARGIN AVG 3Y
-138.44%
OPERATING MARGIN AVG 5Y
-489.66%
OPERATING MARGIN AVG 10Y
-178.05%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.41%
CURRENT VS 3Y AVG
+114.75%
CURRENT VS 5Y AVG
+104.17%
CURRENT VS 10Y AVG
+111.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 744 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.43B
Operating Margin
20.42%
TTM Avg
19.56%
3Y Avg
-138.44%
5Y Avg
-489.66%
Market Cap
$1.43B
Operating Margin
-73.77%
TTM Avg
-87.58%
3Y Avg
-121.21%
5Y Avg
-119.21%
Market Cap
$1.42B
Operating Margin
5.77%
TTM Avg
5.45%
3Y Avg
4.55%
5Y Avg
4.02%
Market Cap
$1.40B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.45B
Operating Margin
0.00%
TTM Avg
17.19%
3Y Avg
8.60%
5Y Avg
8.60%
Market Cap
$1.40B
Operating Margin
-10386.54%
TTM Avg
-88055.27%
3Y Avg
-48544.96%
5Y Avg
-32630.42%
Market Cap
$1.46B
Operating Margin
7.03%
TTM Avg
2.87%
3Y Avg
2.90%
5Y Avg
2.58%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.43B | 20.42% | 19.56% | -138.44% | -489.66% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -73.77% | -87.58% | -121.21% | -119.21% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 5.77% | 5.45% | 4.55% | 4.02% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 0.00% | 17.19% | 8.60% | 8.60% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -10386.54% | -88055.27% | -48544.96% | -32630.42% |
| Certara, Inc. (CERT)vs › | $1.46B | 1.86% | 2.28% | 0.69% | -0.42% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 7.03% | 2.87% | 2.90% | 2.58% |
| GH Research PLC (GHRS)vs › | $1.49B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
99.0%
Operating Margin
20.4%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 243.59% |
| 2026-03-31 | -135.53% |
| 2025-12-31 | 61.80% |
| 2025-09-30 | 45.47% |
| 2025-06-30 | -117.55% |
| 2025-03-31 | -99.16% |
| 2024-12-31 | -22.43% |
| 2024-09-30 | -75.81% |
| 2024-06-30 | -367.52% |
| 2024-03-31 | -587.84% |
| 2023-12-31 | -467.91% |
| 2023-09-30 | -1137.19% |
| 2023-06-30 | -1160.20% |
| 2023-03-31 | -3231.51% |
| 2022-12-31 | -381.51% |
| 2022-09-30 | -2291.80% |
| 2022-06-30 | -2286.10% |
| 2022-03-31 | -3273.09% |
| 2021-12-31 | -3081.80% |
| 2021-09-30 | -32.37% |
| 2021-06-30 | -1.78% |
| 2021-03-31 | -163.25% |
| 2020-12-31 | 55.57% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | -68.35% |
| 2019-12-31 | -741.93% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -535.14% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -337.74% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -238.37% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | -36.50% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -115.25% |
| 2016-09-30 | -33.45% |
| 2016-06-30 | 40.39% |
| 2016-03-31 | -23.41% |
| 2015-12-31 | -88.60% |
| 2015-09-30 | -15.29% |
| 2015-06-30 | 12.56% |
| 2015-03-31 | 8.57% |
| 2014-12-31 | 14.20% |
| 2014-09-30 | 56.43% |
| 2014-06-30 | 33.40% |
| 2014-03-31 | -29.81% |
